Surgical Palliation for Barrett's Esophagus Cancer

Surgical Oncology Clinics of North America

Volumn 18, Issue 3, 2009, Pages 547-560

  Qureshi, Irfan ^a   Shende, Manisha ^a   Luketich, James D ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Barrett's esophagus; Brachytherapy; Esophageal adenocarcinoma; Gastroesophageal reflux; Palliation; Radiotherapy; Stent

Indexed keywords

ALLOY; ANTINEOPLASTIC AGENT; COBALT; IRIDIUM 192; NITINOL; PHOTOFRIN; PROTON PUMP INHIBITOR; STAINLESS STEEL;

ADVERSE OUTCOME; BARRETT ESOPHAGUS; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPHAGIA; ELECTROCOAGULATION; ENTERIC FEEDING; EPITHELIUM DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS FISTULA; ESOPHAGUS PERFORATION; ESOPHAGUS RESECTION; EXTERNAL BEAM RADIOTHERAPY; GASTROESOPHAGEAL REFLUX; LOW LEVEL LASER THERAPY; LOWER ESOPHAGUS SPHINCTER; NEODYMIUM LASER; NUTRITIONAL SUPPORT; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHOTODYNAMIC THERAPY; QUALITY OF LIFE; RADIATION DOSE; RADIATION RESPONSE; REVIEW; STENT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BRACHYTHERAPY; EQUIPMENT DESIGN; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOSCOPY; FORECASTING; GASTROESOPHAGEAL REFLUX; HUMANS; INCIDENCE; LASER THERAPY; PALLIATIVE CARE; PHOTOCHEMOTHERAPY; PROGNOSIS; QUALITY OF LIFE; STENTS; SURVIVAL RATE; UNITED STATES;

EID: 66149125246     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2009.03.009     Document Type: Review

References (64)

1. Armstrong R.A., Blalcock J.B., and Carrera G. Adenocarcinoma of the middle third of the esophagus arising from ectopic gastric mucosa. J Thorac Surg 37 (1959) 398-403
2. Hewlett A.W. The superficial glands of the esophagus. J Exp Med 5 (1901) 319-332
3. Barrett N.R. Chronic peptic ulcer of the oesophagus and 'oesophagitis'. Br J Surg 38 (1950) 175-182
4. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
5. Solaymani-Dodaran M., Logan R.F., West J., et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 53 (2004) 1070-1074
6. Cameron A.J., Lomboy C.T., Pera M., et al. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 109 (1995) 1541-1546
7. Conio M., Cameron A.J., Romero Y., et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 48 (2001) 304-309
8. Rudolph R.E., Vaughan T.L., Storer B.E., et al. Effect of segment length on risk for neoplastic progression in patients with Barrett's esophagus. Ann Intern Med 132 (2000) 612-620
9. Hameeteman W., Tytgat G.N., Houthoff H.J., et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 96 (1989) 1249-1256
10. Shaheen N.J., Crosby M.A., Bozymski E.M., et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 119 (2000) 333-338
11. Devesa S.S., Blot W.J., and Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
12. Blot W.J., Devesa S.S., Kneller R.W., et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265 (1991) 1287-1289
13. Kubo A., and Corley D.A. Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol 99 (2004) 582-588
14. Pohl H., and Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97 (2005) 142-146
15. Bollschweiler E., Wolfgarten E., Gutschow C., et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92 (2001) 549-555
16. el-Serag H.B. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 31 (2002) 421-440 viii
17. Kubo A., and Corley D.A. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 95 (2002) 2096-2102
18. Chen X., and Yang C.S. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis 22 (2001) 1119-1129
19. Siewert J.R., Feith M., Werner M., et al. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 232 (2000) 353-361
20. Dolan K., Sutton R., Walker S.J., et al. New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer 80 (1999) 834-842
21. Wijnhoven B.P., Siersema P.D., Hop W.C., et al. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg 86 (1999) 529-535
22. Theisen J., Peters J.H., and Stein H.J. Experimental evidence for mutagenic potential of duodenogastric juice on Barrett's esophagus. World J Surg 27 (2003) 1018-1020
23. Peters J.H., and DeMeester T.R. Esophagus: anatomy physiology and gastroesophageal reflux disease. In: Greenfield L.J.M., Mulholland M, and Oldham K.T. (Eds). Surgery: scientific principles and practice. 3rd edition (2001), Lippincott, Williams and Wilkins, Philadelphia 671-675
24. Souza R.F., Shewmake K., Pearson S., et al. Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 287 (2004) G743-G748
25. Hamoui N., Peters J.H., Schneider S., et al. Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus. Arch Surg 139 (2004) 712-716 [discussion: 6-7]
26. Raja S., Finkelstein S.D., Baksh F.K., et al. Correlation between dysplasia and mutations of six tumor suppressor genes in Barrett's esophagus. Ann Thorac Surg 72 (2001) 1130-1135
27. Parkin D.M., Bray F.I., and Devesa S.S. Cancer burden in the year 2000. The global picture. Eur J Cancer 37 Suppl 8 (2001) S4-S66
28. Pisani P., Parkin D.M., Bray F., et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83 (1999) 18-29
29. Homs M.Y., Kuipers E.J., and Siersema P.D. Palliative therapy. J Surg Oncol 92 (2005) 246-256
30. Siersema P.D. New developments in palliative therapy. Best Pract Res Clin Gastroenterol 20 (2006) 959-978
31. Bartelsman J.F., Bruno M.J., Jensema A.J., et al. Palliation of patients with esophagogastric neoplasms by insertion of a covered expandable modified Gianturco-Z endoprosthesis: experiences in 153 patients. Gastrointest Endosc 51 (2000) 134-138
32. Baron T.H. Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med 344 (2001) 1681-1687
33. Ell C., and May A. Self-expanding metal stents for palliation of stenosing tumors of the esophagus and cardia: a critical review. Endoscopy 29 (1997) 392-398
34. Vakil N., Morris A.I., Marcon N., et al. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol 96 (2001) 1791-1796
35. Christie N.A., Buenaventura P.O., Fernando H.C., et al. Results of expandable metal stents for malignant esophageal obstruction in 100 patients: short-term and long-term follow-up. Ann Thorac Surg 71 (2001) 1797-1801 [discussion: 801-2]
36. Homs M.Y., Steyerberg E.W., Kuipers E.J., et al. Causes and treatment of recurrent dysphagia after self-expanding metal stent placement for palliation of esophageal carcinoma. Endoscopy 36 (2004) 880-886
37. May A., Hahn E.G., and Ell C. Self-expanding metal stents for palliation of malignant obstruction in the upper gastrointestinal tract. Comparative assessment of three stent types implemented in 96 implantations. J Clin Gastroenterol 22 (1996) 261-266
38. Siersema P.D., Hop W.C., van Blankenstein M., et al. A comparison of 3 types of covered metal stents for the palliation of patients with dysphagia caused by esophagogastric carcinoma: a prospective, randomized study. Gastrointest Endosc 54 (2001) 145-153
39. Botterweck A.A., Schouten L.J., Volovics A., et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29 (2000) 645-654
40. Dua K.S., Kozarek R., Kim J., et al. Self-expanding metal esophageal stent with anti-reflux mechanism. Gastrointest Endosc 53 (2001) 603-613
41. Laasch H.U., Marriott A., Wilbraham L., et al. Effectiveness of open versus antireflux stents for palliation of distal esophageal carcinoma and prevention of symptomatic gastroesophageal reflux. Radiology 225 (2002) 359-365
42. Homs M.Y., Wahab P.J., Kuipers E.J., et al. Esophageal stents with antireflux valve for tumors of the distal esophagus and gastric cardia: a randomized trial. Gastrointest Endosc 60 (2004) 695-702
43. Dormann A.J., Eisendrath P., Wigginghaus B., et al. Palliation of esophageal carcinoma with a new self-expanding plastic stent. Endoscopy 35 (2003) 207-211
44. Pennathur A., Chang A.C., McGrath K.M., et al. Polyflex expandable stents in the treatment of esophageal disease: initial experience. Ann Thorac Surg 85 (2008) 1968-1972 [discussion: 73]
45. Conigliaro R., Battaglia G., Repici A., et al. Polyflex stents for malignant oesophageal and oesophagogastric stricture: a prospective, multicentric study. Eur J Gastroenterol Hepatol 19 (2007) 195-203
46. Evrard S., Le Moine O., Lazaraki G., et al. Self-expanding plastic stents for benign esophageal lesions. Gastrointest Endosc 60 (2004) 894-900
47. Ott C., Ratiu N., Endlicher E., et al. Self-expanding Polyflex plastic stents in esophageal disease: various indications, complications, and outcomes. Surg Endosc 21 (2007) 889-896
48. Verschuur E.M., Homs M.Y., Steyerberg E.W., et al. A new esophageal stent design (Niti-S stent) for the prevention of migration: a prospective study in 42 patients. Gastrointest Endosc 63 (2006) 134-140
49. Verschuur E.M., Repici A., Kuipers E.J., et al. New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. Am J Gastroenterol 103 (2008) 304-312
50. Bethge N., Sommer A., and Vakil N. Treatment of esophageal fistulas with a new polyurethane-covered, self-expanding mesh stent: a prospective study. Am J Gastroenterol 90 (1995) 2143-2146
51. Do Y.S., Song H.Y., Lee B.H., et al. Esophagorespiratory fistula associated with esophageal cancer: treatment with a Gianturco stent tube. Radiology 187 (1993) 673-677
52. Carazzone A., Bonavina L., Segalin A., et al. Endoscopic palliation of oesophageal cancer: results of a prospective comparison of Nd:YAG laser and ethanol injection. Eur J Surg 165 (1999) 351-356
53. Carter R., Smith J.S., and Anderson J.R. Palliation of malignant dysphagia using the Nd:YAG laser. World J Surg 17 (1993) 608-613 [discussion: 14]
54. Litle V.R., Luketich J.D., Christie N.A., et al. Photodynamic therapy as palliation for esophageal cancer: experience in 215 patients. Ann Thorac Surg 76 (2003) 1687-1692 [discussion: 92-3]
55. Lightdale C.J., Heier S.K., Marcon N.E., et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc 42 (1995) 507-512
56. Heier S.K., Rothman K.A., Heier L.M., et al. Photodynamic therapy for obstructing esophageal cancer: light dosimetry and randomized comparison with Nd:YAG laser therapy. Gastroenterology 109 (1995) 63-72
57. Sur R.K., Donde B., Levin V.C., et al. Fractionated high dose rate intraluminal brachytherapy in palliation of advanced esophageal cancer. Int J Radiat Oncol Biol Phys 40 (1998) 447-453
58. Sur R.K., Levin C.V., Donde B., et al. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma-an International Atomic Energy Agency study. Int J Radiat Oncol Biol Phys 53 (2002) 127-133
59. Brewster A.E., Davidson S.E., Makin W.P., et al. Intraluminal brachytherapy using the high dose rate microSelectron in the palliation of carcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 7 (1995) 102-105
60. Homs M.Y., Eijkenboom W.M., Coen V.L., et al. High dose rate brachytherapy for the palliation of malignant dysphagia. Radiother Oncol 66 (2003) 327-332
61. Siersema P.D. Treatment options for esophageal strictures. Nat Clin Pract Gastroenterol Hepatol 5 (2008) 142-152
62. Homs M.Y., Steyerberg E.W., Eijkenboom W.M., et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 364 (2004) 1497-1504
63. Sander R., Hagenmueller F., Sander C., et al. Laser versus laser plus afterloading with iridium-192 in the palliative treatment of malignant stenosis of the esophagus: a prospective, randomized, and controlled study. Gastrointest Endosc 37 (1991) 433-440
64. Brooks J.A., Kesler K.A., Johnson C.S., et al. Prospective analysis of quality of life after surgical resection for esophageal cancer: preliminary results. J Surg Oncol 81 (2002) 185-194